BHVN Stock Recent News
BHVN LATEST HEADLINES
BHV-8000 is a first-in-clinic, brain-penetrant, and selective inhibitor of TYK2 and JAK1 kinases — a novel investigational therapy with the potential to treat the neuroinflammation and immune dysregulation that drives disease progression in Parkinson's disease (PD) Currently, there are no approved disease-modifying therapies for the more than 10 million people living with PD NEW HAVEN, Conn. , May 29, 2025 /PRNewswire/ -- Biohaven Ltd.
Optimized subcutaneous (SC) administration of BHV-1400 achieved rapid, deep, selective, and sustained lowering of Gd-IgA1, differentiating Biohaven's leading TRAP degrader for IgAN from the complement and BLyS/APRIL inhibitor competition. Up to 81% reduction of Gd-IgA1 was observed, with reductions from baseline sustained for weeks after a single SC dose administration.
NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN).
BHV-1510, a highly differentiated Trop2 ADC incorporating the proprietary TopoIx payload, demonstrates early clinical activity and favorable safety profile in Phase 1 study as a monotherapy and in combination with Regeneron's anti-PD-1 cemiplimab. Tumor reduction was observed in the first 6 out of 6 patients treated with BHV-1510 plus cemiplimab including confirmed partial responses First patient dosed with Biohaven's novel, first-in-class FGFR3 directed TopoIx ADC, BHV-1530 Promising progress in the clinic demonstrates potential of Biohaven's innovative, next-generation ADC platform and TopoIx payload, with additional collaboration programs with Merus and GeneQuantum advancing preclinically.
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE:BHVN).
NEW YORK , May 26, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN).
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK , May 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN).
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE:BHVN).